{
    "data": [
        {
            "id": "3736986",
            "type": "article",
            "attributes": {
                "publishOn": "2015-12-07T06:17:09-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Will Generate $3.25 Billion In Free Cash Flow This Year, But I Can't Be Convinced",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50662",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "166662",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3736986-bristol-myers-will-generate-3_25-billion-in-free-cash-flow-this-year-i-cant-be-convinced"
            }
        },
        {
            "id": "3689926",
            "type": "article",
            "attributes": {
                "publishOn": "2015-11-16T18:48:26-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Has No Cure For Your Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3689926-bristol-myers-squibb-no-cure-for-your-portfolio"
            }
        },
        {
            "id": "3408606",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-06T12:52:14-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "HIV, Bristol-Myers Squibb And The Future Of A Neglected Malady",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "83226",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3408606-hiv-bristol-myers-squibb-and-the-future-of-a-neglected-malady"
            }
        },
        {
            "id": "3386915",
            "type": "article",
            "attributes": {
                "publishOn": "2015-08-02T03:04:04-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Had Strong Revenues And Looks To Be Getting Stronger",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3386915-bristol-myers-had-strong-revenues-and-looks-to-be-getting-stronger"
            }
        },
        {
            "id": "3358915",
            "type": "article",
            "attributes": {
                "publishOn": "2015-07-27T07:28:28-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Beat, Raise And A Plethora Of Good News Make It Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3358915-bristol-myers-squibb-beat-raise-and-a-plethora-of-good-news-make-it-attractive"
            }
        },
        {
            "id": "3262085",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-17T11:01:30-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is An Overvalued Company In Quite An Expensive Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41191",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "229675",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3262085-bristol-myers-squibb-is-an-overvalued-company-in-quite-an-expensive-sector"
            }
        },
        {
            "id": "3230566",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-03T13:56:34-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Rides The Immunotherapy Hype Cycle",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "156437",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3230566-bristol-myers-rides-the-immunotherapy-hype-cycle"
            }
        },
        {
            "id": "3227176",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-01T13:13:11-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Asco - The Quest For Immuno-Oncology Biomarkers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3227176-asco-the-quest-for-immuno-oncology-biomarkers"
            }
        },
        {
            "id": "3227156",
            "type": "article",
            "attributes": {
                "publishOn": "2015-06-01T13:09:50-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Asco - Check Mate For Combination Promise And Shortcomings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3227156-asco-check-mate-for-combination-promise-and-shortcomings"
            }
        },
        {
            "id": "3189246",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-17T00:05:47-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Swapping MasterCard For Bristol-Myers In The Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3189246-swapping-mastercard-for-bristol-myers-in-the-growth-portfolio"
            }
        },
        {
            "id": "3183166",
            "type": "article",
            "attributes": {
                "publishOn": "2015-05-14T11:24:35-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Asco Preview - The Eloquence Of Elotuzumab",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3183166-asco-preview-the-eloquence-of-elotuzumab"
            }
        },
        {
            "id": "3116966",
            "type": "article",
            "attributes": {
                "publishOn": "2015-04-29T13:47:54-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Set To Join U.S. Hepatitis C Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3116966-bristol-myers-squibb-set-to-join-u-s-hepatitis-c-market"
            }
        },
        {
            "id": "3023896",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-24T08:52:35-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Opdivo Breezes Through FDA; Multiple Catalysts To Come",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24112",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3023896-bristol-myers-squibbs-opdivo-breezes-through-fda-multiple-catalysts-to-come"
            }
        },
        {
            "id": "3022746",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-23T20:19:01-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Is Playing Chess, Gilead And AbbVie Are Playing Checkers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "152617",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3022746-bristol-myers-is-playing-chess-gilead-and-abbvie-are-playing-checkers"
            }
        },
        {
            "id": "3005556",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-16T22:45:28-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Daclatasvir Is Good, But Gilead's GS-5816 Is Better",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3005556-bristol-myers-squibbs-daclatasvir-is-good-but-gileads-gsminus-5816-is-better"
            }
        },
        {
            "id": "3003426",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-16T09:10:07-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb's Strategic Acquisitions & Agreements: Long Term Growth In Sight?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74855",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3003426-bristol-myers-squibbs-strategic-acquisitions-and-agreements-long-term-growth-in-sight"
            }
        },
        {
            "id": "2977036",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-05T14:11:23-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "FDA Surprises Everyone With Super-Fast Opdivo Lung Cancer Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21877",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2977036-fda-surprises-everyone-with-super-fast-opdivo-lung-cancer-approval"
            }
        },
        {
            "id": "2974706",
            "type": "article",
            "attributes": {
                "publishOn": "2015-03-05T00:22:00-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers' Label Expansion Is Significant, But The Stock Is Not Worth Buying",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80676",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "228914",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2974706-bristol-myers-label-expansion-is-significant-but-the-stock-is-not-worth-buying"
            }
        },
        {
            "id": "2873066",
            "type": "article",
            "attributes": {
                "publishOn": "2015-02-02T02:14:29-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Q4 2014 Earnings Review And The Way Forward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74515",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2873066-bristol-myers-squibb-q4-2014-earnings-review-and-the-way-forward"
            }
        },
        {
            "id": "2850926",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-26T15:21:50-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: What To Expect In Q4 2014 And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74515",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "149572",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2850926-bristol-myers-squibb-what-to-expect-in-q4-2014-and-beyond"
            }
        },
        {
            "id": "2850816",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-26T15:04:29-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Whisper Number Impact: What To Expect From Bristol-Myers Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24051",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2850816-whisper-number-impact-what-to-expect-from-bristol-myers-earnings"
            }
        },
        {
            "id": "2836126",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-21T08:48:41-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: 2.4% Dividend, Impressive Pipeline, Approval Coming Soon",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2836126-bristol-myers-squibb-2_4-percent-dividend-impressive-pipeline-approval-coming-soon"
            }
        },
        {
            "id": "2826116",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-16T09:08:55-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers' Opdivo - The New Cash Cow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "79395",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "148965",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2826116-bristol-myers-opdivo-the-new-cash-cow"
            }
        },
        {
            "id": "2813395",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-12T09:33:03-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Neutral Forecast For Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75405",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2813395-neutral-forecast-for-bristol-myers-squibb"
            }
        },
        {
            "id": "2803935",
            "type": "article",
            "attributes": {
                "publishOn": "2015-01-07T11:19:48-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Has A Real Shot At A Home Run In Hepatitis C",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "148348",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2803935-bristol-myers-squibb-has-a-real-shot-at-a-home-run-in-hepatitis-c"
            }
        }
    ]
}